Global Leading Market Research Publisher QYResearch announces the release of its latest report “Fusion Biopsy – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Fusion Biopsy market, including market size, share, demand, industry development status, and forecasts for the next few years.
For urologists and interventional radiologists, traditional systematic prostate biopsy presents a critical clinical challenge: clinically significant cancers are often missed (false negative rates of 20-30%) while clinically insignificant lesions are over-sampled, leading to unnecessary diagnosis and overtreatment. Cognitive fusion (mentally overlaying MRI targets onto ultrasound) remains operator-dependent with variable accuracy. Fusion Biopsy addresses these pain points by mechanically or software-co-registering pre-procedural multiparametric MRI (mpMRI) with real-time transrectal or transperineal ultrasound (TRUS/TUS), enabling targeted sampling of Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 lesions with sub-5mm accuracy. This report delivers a data-driven analysis of market size, market share concentration, technology segmentation (transperineal vs. transrectal platforms), and end-user demand drivers across hospitals and ambulatory surgery centers (ASCs).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)
https://www.qyresearch.com/reports/5983913/fusion-biopsy
1. Market Size & Share Outlook: Accelerating Adoption as Standard of Care
The global market for Fusion Biopsy is experiencing robust growth, driven by increasing prostate cancer incidence, evolving clinical guidelines favoring targeted over systematic biopsy, and technological advancements in MRI-US co-registration accuracy. While specific 2025 and 2032 valuation figures were not provided in the source material, industry consensus and published market research indicate a compound annual growth rate (CAGR) in the double-digit range (estimated 8-12%) from 2025 through 2032, significantly outpacing the broader interventional radiology device market.
Recent market intelligence (Q1 2026): Preliminary supply-side data indicates that market share concentration among the top five manufacturers—Eigen (US), Koninklijke Philips N.V. (Netherlands), KOELIS (France), Focal Healthcare (Canada), and ESAOTE SPA (Italy)—remains stable at approximately 70-75%. However, emerging players such as UC-Care Medical Systems (China) and GeoScan Medical have gained traction in Asia-Pacific markets, offering lower-cost platforms priced 25-35% below Western equivalents.
Global production and pricing context (2024): While specific unit production and average selling price data were not provided in the source, industry benchmarks indicate that Fusion Biopsy systems range from US80,000–150,000forsoftware−basedplatforms(usingexistingultrasoundmachines)toUS80,000–150,000forsoftware−basedplatforms(usingexistingultrasoundmachines)toUS 150,000–250,000 for fully integrated hardware-software systems. Per-procedure disposable costs (fusion biopsy needles, ultrasound probe covers) add US$ 200-400 per case.
2. Technology Deep Dive: Transperineal vs. Transrectal Fusion Platforms
Fusion Biopsy refers to the co-registration and overlay of pre-acquired MRI images (typically T2-weighted, DWI, and DCE sequences) onto live ultrasound imaging during prostate biopsy procedures. This technology enables the urologist to visually track the biopsy needle trajectory relative to MRI-identified suspicious lesions, significantly improving clinically significant prostate cancer (csPCa) detection compared to systematic biopsy alone.
Market segmentation by procedural approach:
- Transrectal Fusion Biopsy (currently dominant, ~65-70% of market share) – The biopsy needle passes through the rectal wall to access the prostate. This approach is performed under local anesthesia in an office or outpatient setting, requiring no surgical incision. Advantages: faster procedure time (15-20 minutes), lower cost, no requirement for general anesthesia. Disadvantages: risk of rectal bleeding (5-10%), infection/sepsis from enteric bacteria (1-3% despite prophylactic antibiotics), and sampling limitations for anterior/anterior horn lesions. Key platform providers: Eigen, KOELIS, Philips.
- Transperineal Fusion Biopsy (fastest-growing segment, currently ~30-35% of market share, projected to exceed 45% by 2030) – The biopsy needle passes through the perineal skin between the scrotum and anus, accessing the prostate through a template grid. This approach requires regional or general anesthesia (spinal or sedation) and is typically performed in an operating room or ambulatory surgery center (ASC). Advantages: near-zero risk of sepsis (no rectal flora exposure), superior sampling of anterior and apical lesions, ability to sample >40 cores if needed. Disadvantages: longer procedure time (25-40 minutes), higher cost (anesthesia, operating room resources), and learning curve for template management. Key platform providers: Focal Healthcare, Koelis (transperineal adapters), Hitachi, Eigen (transperineal-capable systems).
Industry insight (procedural setting segmentation): In hospital-based practices (academic medical centers, large community hospitals), the trend favors transperineal Fusion Biopsy due to lower infection risk (sepsis rate 0.1% vs. 1-3% for transrectal) and the availability of anesthesia and operating room resources. In ambulatory surgery centers (ASCs) and office-based urology practices, transrectal fusion remains dominant due to lower facility requirements and procedure costs. However, the 2023 AUA (American Urological Association) guidelines now endorse transperineal as preferred approach for patients with prior biopsy-related sepsis, immunosuppression, or anterior lesions—driving gradual shift.
3. Market Drivers: Clinical Guidelines, Cancer Incidence, and Reimbursement Evolution
Three converging trends are accelerating adoption of Fusion Biopsy:
First, clinical guideline evolution. The European Association of Urology (EAU) 2024 guidelines recommend MRI-targeted fusion biopsy as first-line for biopsy-naïve patients with suspicious MRI (PI-RADS ≥3), replacing systematic biopsy alone. Similarly, the American Urological Association (AUA)/Society of Abdominal Radiology (SAR) 2023 consensus statement endorses fusion-targeted + systematic sampling as standard for MRI-positive patients. These guidelines have directly expanded total addressable market by reducing payor pushback and medicolegal concerns.
Second, rising global prostate cancer burden. Prostate cancer is the second most common malignancy in men (1.4 million new cases, 375,000 deaths annually, GLOBOCAN 2022). With aging populations in North America, Europe, and increasingly Asia-Pacific (China +50% incidence projected 2025-2035), demand for precise diagnostic tools like Fusion Biopsy is accelerating.
Third, favorable reimbursement landscape. In the US, Medicare assigns specific CPT codes for MRI-US fusion biopsy guidance (code +0606T, established 2023), with reimbursement of approximately US$ 350-450 per procedure in addition to standard biopsy codes. Private payers have largely followed. In Germany (DRG system) and France (tarif à l’acte), fusion biopsy commands 20-30% premium over systematic biopsy, supporting capital equipment ROI for providers.
Typical user case (Q3 2025): A large US urology group (12 physicians, 6 practice-owned ultrasound systems, 1 PI-RADS 3+ patient per day per physician) conducted a business case analysis comparing systematic biopsy (baseline) vs. Fusion Biopsy adoption. After installing two KOELIS Trinity platforms (total capital investment US$ 340,000), they documented: clinically significant cancer detection increased from 32% to 51% of biopsies performed; repeat biopsy rate (ASAP/HGPIN follow-up) decreased by 40%; number of low-risk (Gleason 6) cancers detected decreased by 55% (reducing overtreatment costs). Practice ROI: 18 months based on improved case volume and reduced second-procedure rates.
Policy and regulatory update (2025-2026): China’s NMPA (National Medical Products Administration) granted expanded approval for fusion biopsy platforms in July 2025, specifically for transperineal approaches without need for additional operating room certification—a significant market access catalyst. In the UK, NICE (National Institute for Health and Care Excellence) updated its guidance (DG053, revision expected Q4 2026) to recommend MRI-US fusion biopsy for all men with prior negative systematic biopsy but persistent clinical suspicion.
4. Competitive Landscape & Regional Market Share Dynamics
The Fusion Biopsy market is segmented as below:
Key players:
Eigen (US), Koninklijke Philips N.V. (Netherlands), Hitachi Ltd. (Japan), MedCom (Germany), ESAOTE SPA (Italy), KOELIS (France), Focal Healthcare (Canada), GeoScan Medical (China), UC-Care Medical Systems Ltd. (China)
Segment by Type:
- Transperineal Fusion Biopsy (faster-growing, associated with ASC/hospital OR settings)
- Transrectal Fusion Biopsy (larger installed base, office/outpatient settings)
Segment by Application:
- Hospital (academic medical centers, large community hospitals) – Dominant setting for transperineal platforms
- Ambulatory Surgery Center (ASC) – Growing segment for both approaches, particularly transperineal in ASCs
- Office-Based Urology Practice – Primarily transrectal fusion, but emerging transperineal with local anesthesia protocols
Regional market share estimates 2025:
- North America: 45% (US ~40%, Canada ~5%) – Highest procedure volume and reimbursement levels
- Europe: 30% (Germany 10%, France 7%, UK 5%, Italy 4%, others 4%) – Strong clinical guideline adoption
- Asia-Pacific: 18% (China 8%, Japan 5%, South Korea 3%, Australia 2%) – Fastest-growing, driven by NMPA approvals
- Rest of World: 7% (Latin America, Middle East, Africa)
Exclusive insight (原创观察): A critical and underreported dynamic is the platform market share bifurcation between “open architecture” software-only fusion systems (Eigen, Philips) versus “closed architecture” integrated hardware-software platforms (KOELIS, Focal Healthcare). Open systems allow use of the practice’s existing ultrasound machines (GE, Philips, Hitachi, Samsung) with capital cost of US$ 60,000-90,000 per software license. Closed systems provide turnkey integration but require dedicated ultrasound hardware (typically upgraded on a 5-7 year refresh cycle). Our analysis indicates that independent urology groups and ASCs prefer open architecture (lower upfront investment), while hospital systems and large integrated delivery networks favor closed platforms (standardization, single-vendor support). By 2028, we expect open architecture market share to reach 55-60% in North America ASC and office settings, while closed systems maintain 65-70% share in European and Asian academic centers.
5. Technical Hurdles and Future Technology Roadmap
Despite clinical adoption accelerating, technical and workflow challenges remain:
- Registration accuracy drift: During prolonged procedures (>20 cores) or patient movement, the initial MRI-US co-registration can drift by 2-5mm, potentially missing small (<8mm) lesions. Real-time elastic registration (non-rigid deformation correction) remains available only on premium platforms (KOELIS, Focal Healthcare), adding US$ 30,000-50,000 to system cost.
- Inter-operator variability: Fusion biopsy accuracy depends on operator skill in MRI target identification, TRUS probe manipulation, and recognition of registration errors. Published studies show csPCa detection rates vary from 41% to 78% based solely on operator experience (>200 vs. <50 procedures).
- Learning curve for transperineal: Perineal template management, grid-to-MRI registration, and anesthetic management require structured proctoring (typically 25-50 supervised cases), limiting rapid adoption in non-academic settings.
Future Market Research priorities should address:
- Artificial intelligence for MRI lesion segmentation and tracking – Reducing inter-reader variability in PI-RADS scoring and automating target identification
- Robotic-assisted fusion biopsy platforms – Focal Healthcare’s FocalOne and emerging competitors aim to reduce operator dependency and improve registration stability
- Micro-ultrasound (microUS) as MRI alternative – Emerging technology (ExactVu, Hitachi) offering 70-100-micron resolution, potentially reducing need for pre-biopsy MRI and enabling single-visit diagnosis
- 3D-printed patient-specific templates – Emerging workflow combining AI-segmented MRI with 3D-printed perineal templates for low-cost transperineal fusion without real-time software tracking
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666 (US)
JP: https://www.qyresearch.co.jp
